Etiome

Etiome is a Flagship Pioneering company focused on developing preemptive medicines for better health. The company's Temporal Biodynamics™ platform is the first end-to-end technology to characterize disease with increased resolution over time, enabling development of Biostaged Medicines — stage-specific therapies delivered to the right patient population at the right time. By building detailed models of molecular changes over the course of disease, Etiome aims to slow, prevent, or reverse damage from disease progression. Target conditions include Parkinson's disease, rheumatoid arthritis, and metabolic dysfunction-associated steatohepatitis (MASH). The company leverages AI and health data to analyze biological changes and identify biomarkers at various disease stages for early intervention.